• KOLs Community
    • Ischemic
    • Ischemic Stroke
    • Stephen M Davis
    • Stephen M Davis

      Stephen M Davis

      Geoffrey A. Donnan, is Professor of Neurology, Melbourne Brain Centre and Department of Neurology, Royal Melbourne Hospital; and Faculty of Medicine, Dentistry and Health ...



      KOL Resume for Stephen M Davis


      Geoffrey A. Donnan, is Professor of Neurology, Melbourne Brain Centre and Department of Neurology, Royal Melbourne Hospital; and Faculty of Medicine, Dentistry and Health Sciences, Department of Medicine, The University of Melbourne, Melbourne, Australia (ORCID: https://orcid.org/0000-0001-6324-3403).

      Anne W. Alexandrov, is Professor of Nursing, Mobile Stroke Unit, Department of Neurology, Colleges of Nursing and Medicine, University of Tennessee Health Science Center, Memphis, TN (ORCID: https://orcid.org/0000-0002-4060-6766).

      The Melbourne Brain Centre at the Royal Melbourne Hospital and the University of Melbourne, Parkville, Australia


      Department of Medicine and Neurology, Melbourne Brain Centre (F.C.N., N.Y., G.S., S.M.D., B.C.V.C.), Royal Melbourne Hospital, University of Melbourne, Parkville, Australia.

      Melbourne Brain Centre at the Royal Melbourne Hospital and University of Melbourne, Melbourne, VIC, Australia


      Department of Health Policy, Management, and Leadership, Robert C. Byrd Health Sciences Center, School of Public Health, West Virginia University, PO Box 9190, 26506-9190, Morgantown, WV, USA

      Royal Melbourne Hospital, Parkville, Melbourne, Victoria, Australia


      Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia


      Melbourne Brain Centre at The Royal Melbourne Hospital, University of Melbourne, Australia

      Department of Emergency Medicine, West Virginia University, Morgantown, WV, United States


      Department of Neurology, Royal Melbourne Hospital, the University of Melbourne, Victoria, Australia

      Presented in part at the International Stroke Conference of the American Heart Association, Houston, TX, February 22-24, 2017.

      Guest Editor for this article was Giuseppe Lanzino, MD.



      Stephen M Davis: Influence Statistics

      Sample of concepts for which Stephen M Davis is among the top experts in the world.
      Concept World rank
      lesion reversal #1
      arm 3 eligibility #1
      patients 08mg #1
      abnormalities occur #1
      eye randomization #1
      broad community support #1
      poststroke hyperglycemia psh #1
      score severe disability #1
      toruloma #1
      ctp flair #1
      reliability existing scales #1
      aerosol particles subjects #1
      atypical presentations health #1
      hct increasing hct #1
      pwi lesions patients #1
      ctasi poor outcome #1
      auc glutamate creatine #1
      infarction relationship #1
      vbao ctasi #1
      core mismatch #1
      p0001 deterioration #1
      mirror homologue #1
      dwi acute dwi #1
      risk factors bgh #1
      neurosurgery fast #1
      ror053 p002 #1
      ultraearly #1
      brainstem adjustment #1
      vasospasm hypoperfusion #1
      worse stroke outcome #1
      wireless accelerometry setting #1
      iecg paf #1
      3 months needle #1
      patients neurosurgery #1
      p002 acute #1
      haemorrhage morbidity #1
      icaruss #1
      lvo outcome #1
      rmtt lesions #1
      collateral quality #1
      hematoma volume β #1
      61 patients hypertension #1
      e9673 #1
      iqr lvo #1
      phe 72 hours #1
      placebo infarct growth #1
      sbp rftd #1
      hct rtpa administration #1
      treatment nwh #1
      inr hematoma volumes #1


      Prominent publications by Stephen M Davis

      KOL-Index: 23358

      BACKGROUND: Alteplase is effective for treatment of acute ischaemic stroke but debate continues about its use after longer times since stroke onset, in older patients, and among patients who have had the least or most severe strokes. We assessed the role of these factors in affecting good stroke outcome in patients given alteplase.

      METHODS: We did a pre-specified meta-analysis of individual patient data from 6756 patients in nine randomised trials comparing alteplase with placebo or open ...

      Known for Stroke Severity | Treatment Delay | Randomised Trials | Individual Patient Data | Patients Alteplase
      KOL-Index: 17620

      IMPORTANCE: Endovascular thrombectomy with second-generation devices is beneficial for patients with ischemic stroke due to intracranial large-vessel occlusions. Delineation of the association of treatment time with outcomes would help to guide implementation.

      OBJECTIVE: To characterize the period in which endovascular thrombectomy is associated with benefit, and the extent to which treatment delay is related to functional outcomes, mortality, and symptomatic intracranial ...

      Known for Endovascular Thrombectomy | Medical Therapy | 3 Months | Ard 95 | Symptom Onset
      KOL-Index: 16307

      BACKGROUND: Randomised trials have shown that alteplase improves the odds of a good outcome when delivered within 4·5 h of acute ischaemic stroke. However, alteplase also increases the risk of intracerebral haemorrhage; we aimed to determine the proportional and absolute effects of alteplase on the risks of intracerebral haemorrhage, mortality, and functional impairment in different types of patients.

      METHODS: We used individual patient data from the Stroke Thrombolysis Trialists' (STT) ...

      Known for Intracerebral Haemorrhage | Acute Ischaemic Stroke | Patients Alteplase | Individual Patient Data | Secondary Analysis
      KOL-Index: 15833

      The use of perfusion imaging to guide selection of patients for stroke thrombolysis remains controversial because of lack of supportive phase three clinical trial evidence. We aimed to measure the outcomes for patients treated with intravenous recombinant tissue plasminogen activator (rtPA) at a comprehensive stroke care facility where perfusion computed tomography was routinely used for thrombolysis eligibility decision assistance. Our overall hypothesis was that patients with 'target' ...

      Known for Computed Tomography | Target Mismatch | Stroke Thrombolysis | Treatment Decision | Primary Analysis
      KOL-Index: 15790

      BACKGROUND: Whether intravenous tissue plasminogen activator (alteplase) is effective beyond 3 h after onset of acute ischaemic stroke is unclear. We aimed to test whether alteplase given 3-6 h after stroke onset promotes reperfusion and attenuates infarct growth in patients who have a mismatch in perfusion-weighted MRI (PWI) and diffusion-weighted MRI (DWI).

      METHODS: We prospectively and randomly assigned 101 patients to receive alteplase or placebo 3-6 h after onset of ischaemic ...

      Known for Alteplase Placebo | Patients Mismatch | Reperfusion Infarct Growth | Thrombolytic Evaluation | Pwi Dwi
      KOL-Index: 15394

      BACKGROUND: High blood pressure is a prognostic factor for acute stroke, but blood pressure variability might also independently predict outcome. We assessed the prognostic value of blood pressure variability in participants of INTERACT2, an open-label randomised controlled trial (ClinicalTrials.gov number NCT00716079).

      METHODS: INTERACT2 enrolled 2839 adults with spontaneous intracerebral haemorrhage (ICH) and high systolic blood pressure (150-220 mm Hg) without a definite indication or ...

      Known for Blood Pressure Variability | Acute Intracerebral Haemorrhage | Controlled Trial | Secondary Outcome | Mm Hg
      KOL-Index: 15137

      BACKGROUND: Intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality. Among patients who undergo computed tomography (CT) within three hours after the onset of intracerebral hemorrhage, one third have an increase in the volume of the hematoma related to subsequent bleeding. We sought to determine whether recombinant activated factor VII (rFVIIa) can reduce hematoma growth after intracerebral hemorrhage.

      METHODS: We randomly assigned 399 ...

      Known for Intracerebral Hemorrhage | Rfviia Groups | 80 Microg | Patients Placebo | Activated Factor
      KOL-Index: 14887

      BACKGROUND: Intravenous infusion of alteplase is used for thrombolysis before endovascular thrombectomy for ischemic stroke. Tenecteplase, which is more fibrin-specific and has longer activity than alteplase, is given as a bolus and may increase the incidence of vascular reperfusion.

      METHODS: We randomly assigned patients with ischemic stroke who had occlusion of the internal carotid, basilar, or middle cerebral artery and who were eligible to undergo thrombectomy to receive tenecteplase ...

      Known for Ischemic Stroke | Tenecteplase Alteplase | Symptom Onset | 45 Hours | Death 90
      KOL-Index: 14505

      BACKGROUND: CHADS2 and CHA2DS2-VASc scores are validated tools for assessing stroke risk in patients with atrial fibrillation (AF). We investigated whether these scores are associated with 3-month stroke outcomes and evaluated the utility of these scores in stratifying 3-month stroke outcomes in both patients with and without AF.

      METHODS: We analysed 6,612 acute ischaemic stroke patients from the Virtual International Stroke Trials Archive who received either placebo or ineffective ...

      Known for Stroke Chads2 | Vasc Scores | Atrial Fibrillation | 3 Months | Intravenous Aged Aged
      KOL-Index: 14055

      Importance: Intravenous thrombolysis with tenecteplase improves reperfusion prior to endovascular thrombectomy for ischemic stroke compared with alteplase.

      Objective: To determine whether 0.40 mg/kg of tenecteplase safely improves reperfusion before endovascular thrombectomy vs 0.25 mg/kg of tenecteplase in patients with large vessel occlusion ischemic stroke.

      Design, Setting, and Participants: Randomized clinical trial at 27 hospitals in Australia and 1 in New Zealand using open-label ...

      Known for Ischemic Stroke | Tenecteplase Patients | Endovascular Thrombectomy | Large Vessel | Intravenous Thrombolysis
      KOL-Index: 13936

      The question of whether influenza is transmitted to a significant degree by aerosols remains controversial, in part, because little is known about the quantity and size of potentially infectious airborne particles produced by people with influenza. In this study, the size and amount of aerosol particles produced by nine subjects during coughing were measured while they had influenza and after they had recovered, using a laser aerosol particle spectrometer with a size range of 0.35 to 10 ...

      Known for Aerosol Particles | Influenza Patients | Size Range | 10 Μm | Produced Cough
      KOL-Index: 13877

      BACKGROUND: Global stroke epidemiology is changing rapidly. Although age-standardized rates of stroke mortality have decreased worldwide in the past 2 decades, the absolute numbers of people who have a stroke every year, and live with the consequences of stroke or die from their stroke, are increasing. Regular updates on the current level of stroke burden are important for advancing our knowledge on stroke epidemiology and facilitate organization and planning of evidence-based stroke ...

      Known for Global Burden | Hemorrhagic Stroke | Mortality Dalys | Incidence Prevalence | Developing Countries
      KOL-Index: 13862

      Background and Purpose- The volume of estimated ischemic core using computed tomography perfusion (CTP) imaging can identify ischemic stroke patients who are likely to benefit from reperfusion, particularly beyond standard time windows. We assessed the accuracy of pretreatment CTP estimated ischemic core in patients with successful endovascular reperfusion. Methods- Patients from the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) and EXTEND-IA TNK ...

      Known for Ischemic Core | Computed Tomography Perfusion | 24 Hours | Ctp Imaging | Stroke Patients
      KOL-Index: 13830

      BACKGROUND: Early administration of intravenous recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome. Previous analysis of combined data from individual patients suggested potential benefit beyond 3 h from stroke onset. We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis.

      METHODS: We added data from ECASS III (821 patients) and EPITHET ...

      Known for Intravenous Alteplase | Stroke Onset | Randomized Controlled Trials | Pooled Analysis | Activator Treatment
      KOL-Index: 13718

      BACKGROUND: Atrial fibrillation is associated with greater baseline neurological impairment and worse outcomes following ischemic stroke. Previous studies suggest that greater volumes of more severe baseline hypoperfusion in patients with history of atrial fibrillation may explain this association. We further investigated this association by comparing patients with and without atrial fibrillation on initial examination following stroke using pooled multimodal magnetic resonance imaging ...

      Known for Atrial Fibrillation | Hemorrhagic Transformation | Stroke Outcome | 95 Confidence Interval | Intravenous Aged Aged

      Key People For Ischemic Stroke

      Top KOLs in the world
      Ralph L Sacco
      ischemic stroke northern manhattan study carotid plaque
      Harold P Jr Adams
      ischemic stroke cerebral infarction subarachnoid hemorrhage
      José Biller
      ischemic stroke cerebral infarction neurologic complications
      Laurens Jaap Kappelle
      ischemic stroke type 2 diabetes cognitive impairment
      Geoffrey Alan Donnan
      ischemic stroke atrial fibrillation intracerebral haemorrhage
      Jeffrey L Saver
      acute ischemic stroke endovascular thrombectomy united states

      Stephen M Davis:Expert Impact

      Concepts for whichStephen M Davishas direct influence:Ischemic stroke,  Intracerebral hemorrhage,  Acute stroke,  Acute ischemic stroke,  Atrial fibrillation,  United states,  Stroke patients,  Thrombolytic therapy.

      Stephen M Davis:KOL impact

      Concepts related to the work of other authors for whichfor which Stephen M Davis has influence:Ischemic stroke,  Intracerebral hemorrhage,  Intravenous thrombolysis,  Blood pressure,  Mechanical thrombectomy,  Endovascular treatment,  Functional outcome.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Geoffrey A. Donnan, is Professor of Neurology, Melbourne Brain Centre and Department of Neurology, Royal Melbourne Hospital; and Faculty of Medicine, Dentistry and Health Sciences, Department of Medicine, The University of Melbourne, Melbourne, Austr

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.